Home›CJC-1295 (without DAC)›Legal status
Is CJC-1295 (without DAC) legal? FDA status and US regulatory standing
Current status
Compounding nomination withdrawn. CJC-1295 (without DAC) was nominated for the FDA bulk drug substances compounding list and was previously placed in a safety-review category before the nomination was withdrawn, so it does not appear on the current bulk substances lists. CJC-1295 is a synthetic GHRH analog with no FDA approval and no bulk compounding authorization. Federal compliance for compounding facilities is uncertain. Clinical use occurs in a regulatory gray area.
Primary source: www.fda.gov
Federal legal status
FDA approval status
Not FDA-approved. Not on the FDA 503A or 503B bulk substances lists. CJC-1295 (with or without DAC) is an unapproved research peptide.
Compounding pharmacy rules (federal)
CJC-1295 is not on the FDA bulk substances list for 503A or 503B compounding. FDA has issued guidance indicating that unapproved peptides like CJC-1295 may not be lawfully compounded by facilities subject to FDA oversight. Providers offering it operate in a legally uncertain space under federal law.
Also known as
Modified GRF (1–29) · Mod GRF 1–29 · DAC:GRF
About CJC-1295 (without DAC)
CJC-1295 is a synthetic analog of GHRH designed for extended half-life through Drug Affinity Complex (DAC) technology. The DAC version binds to albumin in the bloodstream, extending its half-life significantly compared to sermorelin. It is often studied in combination with ipamorelin.
Frequently asked questions
- What is the difference between CJC-1295 with DAC and without DAC?
- CJC-1295 with DAC binds to albumin and has a half-life of approximately 1–2 weeks, allowing less frequent dosing. CJC-1295 without DAC (also called Modified GRF 1-29) has a much shorter half-life of approximately 30 minutes, similar to sermorelin, and requires more frequent administration.
State-level notes
Compounding and prescribing rules are administered by state pharmacy boards and vary by state. Federal FDA status (above) applies nationwide.
Content review: Regulatory status is sourced from the linked primary records and reviewed by the PeptideBase editorial team. This page is educational — not legal or medical advice. Last reviewed: .